Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data

Journal of Thoracic Disease

Volumn 2, Issue 4, 2010, Pages 199-204

  McKeage, Mark J ^a   Jameson, Michael B ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAIKATO HOSPITAL   (New Zealand)

Author keywords

ASA404; Clinical trial; Non small cell lung carcinoma; Phase II; Safety

Indexed keywords

EID: 79959586755     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2010.02.04.1     Document Type: Article

References (13)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
3. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:191-202.
4. Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol 2008;26:3543-51.
5. Chustecka Z. Phase 3 trial of motesanib in non-small-cell lung cancer suspended. Available from: [http://www.medscape.com/ viewarticle/584015.
6. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004;22:2184-91.
7. Scagliotti GV, Novello S, Von Pawel J, Reck M, Pereira J, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-42.
8. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-8.
9. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-12.
10. McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65:192-7.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
13. ATTRACT-1 phase III trial of ASA404 halted following interim analysis. Available from: http://www.antisoma.com/asm/media/press/ pr2010/2010-03-29/.